Felis ISSN 2398-2950

Therapeutics: musculoskeletal system

Contributor(s): Kyle Braund, Peter Hanson, Lauren Trepanier, Vericore Veterinary Products, Jo Murrell

Introduction

  • This section will cover the pharmacological effects of non-steroidal anti-inflammatory drugs (NSAIDs), other joint modifying agents, topical anti-inflammatory agents, cytotoxic immunosuppressants and disease-modifying drugs, and other oral analgesics to control musculoskeletal pain in cats. 

Non-steroidal anti-inflammatory drugs (NSAIDs)

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Other anti-inflammatory drugs

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Topical anti-inflammatory preparations

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Cytotoxic immunosuppressants and disease-modifying drugs

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Other oral analgesics used to control musculoskeletal pain in cats

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references from PubMed and VetMedResource.
  • Kongara K, Chambers J P (2018) Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy. Vet Med (Auckl) 9, 53-61 PubMed Full Article.
  • KuKanich B (2013) Outpatient Oral Analgesics in Dogs and Cats Beyond Nonsteroidal Antiinflammatory Drugs: An Evidence-based Approach. Vet Clin North Am Small Anim Pract 43 (5), 1109-1125 PubMed.
  • Gunew M N, Menrath V H, Marshall R D (2008) Long-term safety, efficacy and palatability of oral meloxicam at 0.01-0.03 mg/kg for treatment of osteoarthritic pain in cats. J Feline Med Surg 10 (3), 235-241 PubMed.
  • Gassel A D, Tobias K M & Cox S K (2006) Disposition of deracoxib in cats after oral administration. JAAHA 42 (3), 212-217 PubMed.
  • McCann M E, Rickes E L, Hora D F et al (2005) In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia. Am J Vet Res 66 (7), 1278-1284 PubMed.
  • Behrend E N, Kemppainen R J (1997) Glucocorticoid therapy. Pharmacology, indications, and complications. Vet Clin North Am Small Anim Pract 27 (2), 187-213 PubMed.


ADDED